Berberrubine chloride: IMPDH2 and TrxR Inhibitor for Cancer and Metabolic Research

Executive Summary: Berberrubine chloride (N2089, APExBIO) is a natural isoquinoline alkaloid derivative with multi-target inhibitory actions, notably against IMPDH2 (IC₅₀ 2.37 μM), TrxR (IC₅₀ 5.0 μM), and vitamin K epoxide reductase, with selectivity over IMPDH1 [1]. It suppresses colorectal and non-small cell lung cancer cell proliferation in vitro at 10–80 μM, modulates urate transporters for anti-hyperuricemia, and regulates the JAK2/STAT3 and NF-κB pathways. Oral dosing (6.25–200 mg/kg/day) in animal models reduces thrombosis and tumor growth without increasing bleeding risk [1]. Its solubility, storage, and workflow parameters are well-defined for reproducible research.

Biological Rationale

Berberrubine chloride (9-hydroxy-10-methoxy-5,6-dihydro-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-7-ium chloride) is a metabolite of berberine. It is found in traditional Chinese medicines such as Coptis chinensis [1]. The compound displays a broad spectrum of biological activities: antibacterial, anti-inflammatory, hypoglycemic, anti-hyperuricemic, anti-thrombotic, and anti-tumor. These effects are mediated by modulation of key metabolic, signaling, and enzymatic pathways relevant to cancer, metabolic, and thrombotic disorders. In particular, inhibition of inosine monophosphate dehydrogenase 2 (IMPDH2) and thioredoxin reductase (TrxR) disrupts nucleotide biosynthesis and redox regulation in cancer cells, leading to growth inhibition [APExBIO]. Regulation of urate transporters and the vitamin K catalytic cycle underlies its metabolic and anti-thrombotic actions.

Mechanism of Action of Berberrubine chloride

• IMPDH2 Inhibition: Berberrubine chloride competitively inhibits IMPDH2 (IC₅₀ = 2.37 μM), with selectivity over IMPDH1, limiting guanine nucleotide synthesis in proliferating cells [1].
• Thioredoxin Reductase Inhibition: It inhibits TrxR with an IC₅₀ of 5.0 μM by targeting the Sec498 residue, affecting redox homeostasis.
• Vitamin K Cycle Regulation: Molecular docking and in vivo data demonstrate inhibition of vitamin K epoxide reductase (VKOR) and γ-glutamyl carboxylase (GGCX), which prolongs prothrombin time and reduces thrombosis in mice [1].
• Urate Transporter Modulation: It inhibits URAT1 and GLUT9, while upregulating OAT1/3 and ABCG2, lowering serum uric acid in animal models.
• Signaling Pathway Suppression: The compound inhibits NF-κB nuclear translocation, modulates JAK2/STAT3 signaling, and activates GSTM2 via SP1 transcription factor and DNA demethylation.
• Topoisomerase II Inhibition: Berberrubine chloride also suppresses topoisomerase II-mediated DNA cleavage, contributing to anti-proliferative effects.

Evidence & Benchmarks

• Berberrubine chloride inhibits IMPDH2 with an IC₅₀ of 2.37 μM, showing selectivity over IMPDH1 (Wang et al., DOI).
• In vitro, it suppresses proliferation of colorectal cancer cell lines (SW620, LS174T) at 10–80 μM and NSCLC A549 cells at 20–50 μM (APExBIO, product page).
• In vivo, oral administration at 6.25–200 mg/kg/day reduces carrageenan-induced thrombosis without increasing bleeding risk in mice (Wang et al., DOI).
• Berberrubine chloride inhibits TrxR (IC₅₀ 5.0 μM) and modulates the vitamin K catalytic cycle, prolonging prothrombin time (Wang et al., DOI).
• It enhances cisplatin chemosensitivity in NSCLC A549 cells at 20 μM (APExBIO, product page).
• Serum uric acid reduction via inhibition of URAT1/GLUT9 and upregulation of OAT1/3/ABCG2 is observed in hyperuricemia animal models (APExBIO, product page).

For more on assay optimization, see this guide, which focuses on cell viability and cytotoxicity protocols—a complementary resource to the mechanistic detail provided here.

Applications, Limits & Misconceptions

Berberrubine chloride’s validated targets and multi-mechanistic actions make it a versatile tool for translational research:

• Cancer research: Inhibits tumor cell proliferation and enhances chemosensitivity (NSCLC, colorectal models).
• Metabolic disease: Modulates urate transporters for gout/hyperuricemia research.
• Thrombosis: Regulates vitamin K cycle, reducing thrombus formation without excess bleeding.
• Inflammation: Suppresses NF-κB and JAK2/STAT3 signaling pathways.

Common Pitfalls or Misconceptions

• Berberrubine chloride is insoluble in water and ethanol; DMSO (≥6.42 mg/mL with warming/ultrasonics) is required for preparation.
• It is not a direct substitute for berberine; it exhibits distinct selectivity and potency profiles.
• Anti-thrombotic effects occur without increased bleeding risk in mice, but human risk is uncharacterized [1].
• In vitro activity does not guarantee in vivo efficacy due to pharmacokinetic differences.
• High concentrations may exert off-target toxicity—strict dosing is advised.

Workflow Integration & Parameters

• Solubility: Dissolve in DMSO (≥6.42 mg/mL) with gentle warming and ultrasonication; avoid water or ethanol.
• Storage: Store as a solid at –20°C, protected from light and moisture (APExBIO guidelines).
• In vitro use: Typical concentrations—colorectal cancer (10–80 μM), NSCLC (20–50 μM), ARPE-19 retinal cells (0.2–25 μM), bladder cancer BFTC 905 (50 μM).
• In vivo dosing: 6.25–200 mg/kg/day, adjusted by disease model and endpoint.
• Assay planning: See the N2089 kit details and protocol optimization guidance for reproducibility tips. This article expands on mechanistic context and disease-specific parameters compared to previous protocol-focused summaries.

Conclusion & Outlook

Berberrubine chloride (APExBIO N2089) is a rigorously characterized tool compound for research in oncology, metabolic, and thrombotic diseases. Its multi-target action, reproducible benchmarks, and defined handling make it suitable for mechanistic and translational studies. Future directions include further pharmacokinetic profiling and clinical translation, particularly in anti-thrombotic and anti-cancer applications. For full details and ordering, refer to the Berberrubine chloride product page.